Drugs / BA3011
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03425279 | Feb 2018 → Jan 2025 | myxofibrosarcoma, undifferentiated pleomorphic sarcoma | BioAtla, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04918186 | May 2022 → Dec 2026 expected | ovarian cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 10
| Date | Issuer | Release |
|---|---|---|
| 2025-11-07 | BioAtla, Inc. | Results BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas bioatla.com ↗
Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents |
| 2025-10-03 | BioAtla, Inc. | Results BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 bioatla.com ↗
Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC |
| 2024-12-16 | BioAtla, Inc. | Results BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting bioatla.com ↗
Among all 78 patients treated with Mec-V, 58% of those with tumors harboring mKRAS were alive at one year compared to only 23% lacking the mutation, |
| 2024-07-25 | BioAtla, Inc. | Results BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day bioatla.com ↗
“It is promising to see confirmed responses following mecbotamab vedotin treatment among heavily pretreated patients with tumors expressing KRAS mutations, including in a patient previously treated with a KRAS inhibitor,” said Dr. Yau. |
| 2023-12-05 | BioAtla, Inc. | Results BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event bioatla.com ↗
Results from the Phase 2 BA3011 clinical non-small cell lung cancer (NSCLC) study demonstrated promising clinical benefits in heavily pre-treated non-squamous histology patients across key endpoints |
| 2023-01-10 | BioAtla, Inc. | Results BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones bioatla.com ↗
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled |
| 2022-11-03 | BioAtla, Inc. | Results BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress bioatla.com ↗
Also, we continue to observe encouraging antitumor activity in our Phase 2 BA3011 sarcoma study. |
| 2022-08-09 | BioAtla, Inc. | Results BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress bioatla.com ↗
We are very encouraged by our Phase 2 NSCLC preliminary observations, which are consistent with results from our Phase 1 NSCLC and Phase 2 sarcoma studies. |
| 2022-05-04 | BioAtla, Inc. | Results BioAtla Reports First Quarter 2022 Financial Results and Highlights Recent Progress bioatla.com ↗
BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for treatment of solid tumors, today announced its financial results for the first quarter ended March 31, 2022, and provided an interim topline data update from the mecbotamab vedotin (BA3011) Phase 2 study in sarcoma as well as an operational update on its ongoing clinical programs, including BA3011, ozuriftamab vedotin (BA3021) and CAB-CTLA-4 (BA3071) addressing multiple tumor types. |
| 2018-01-22 | BioAtla, Inc. | Regulatory BioAtla Announces FDA Clearance of IND Application for CAB-AXL-ADC Therapeutic bioatla.com ↗
BioAtla © LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today the U.S. Food and Drug Administration (FDA) has cleared BioAtla's Investigational New Drug application (IND) for BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), in patients with solid tumors. |
All press releases naming this drug 13 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BA3011 | “mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗ |
| Known as | CAB-AXL-ADC | “mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗ |
| Known as | mecbotamab vedotin | “mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗ |
| Modality | Other / unclassified | “a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC)” NCT03425279 ↗ |
| Target | AXL | “AXL-targeted” NCT03425279 ↗ |